PILOCARPINE NITRATE

First marketed in 1921

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C11H16N2O2.HNO3
Molecular Weight	271.2698
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O[N+]([O-])=O.CC[C@H]1[C@@H](CC2=CN=CN2C)COC1=O

InChI

InChIKey=PRZXEPJJHQYOGF-GNAZCLTHSA-N

InChI=1S/C11H16N2O2.HNO3/c1-3-10-8(6-15-11(10)14)4-9-5-12-7-13(9)2;2-1(3)4/h5,7-8,10H,3-4,6H2,1-2H3;(H,2,3,4)/t8-,10-;/m0./s1

HIDE SMILES / InChI

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/200890s001lbl.pdf | https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/020237s012lbl.pdf

Pilocarpine is an alkaloid extracted from plants of the genus Pilocarpus. The drug stimulates the muscarinic receptors (especially M3, which is expressed in smooth muscles and glands) and thus induces salivation, hypertension and water intake. Pilocarpine was appoved by FDA for the alleviation of symptoms of xerostomia in patients who have undergone radiation therapy to their head and neck cancer and in patients with Sjogren's Syndrome. Ophthalmic solution of the drug is prescribed for the treatment of glaucoma, ocular hypertension, postoperative elevated intraocular pressure, etc.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Muscarinic acetylcholine receptor M3 159 Target ID: P20309 Gene ID: 1131.0 Gene Symbol: CHRM3 Target Organism: Homo sapiens (Human) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/200890s001lbl.pdf \| https://www.ncbi.nlm.nih.gov/pubmed/11392632	Agonist 2678

Conditions

Condition	Modality	Highest Phase	Product
Head and neck cancer 50 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/020237s012lbl.pdf	Secondary	Approved 8429	SALAGEN Approved Use SALAGEN Tablets are indicated for 1) the treatment of symptoms of dry mouth from salivary gland hypofunction caused by radiotherapy for cancer of the head and neck; and 2) the treatment of symptoms of dry mouth in patients with Sjogren's syndrome. Launch Date 1994
Sjogren's syndrome 8 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/020237s012lbl.pdf	Palliative	Approved 8429	SALAGEN Approved Use SALAGEN Tablets are indicated for 1) the treatment of symptoms of dry mouth from salivary gland hypofunction caused by radiotherapy for cancer of the head and neck; and 2) the treatment of symptoms of dry mouth in patients with Sjogren's syndrome. Launch Date 1994
Open-angle glaucoma 51 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/200890s001lbl.pdf	Primary	Approved 8429	ISOPTO CARPINE Approved Use Isopto Carpine is a muscarinic cholinergic agonist indicated for (1) the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; (2) the management of acute angle-closure glaucoma; (3) the prevention of postoperative elevated IOP associated with laser surgery; (4) the induction of miosis. Launch Date 2010
Ocular hypertension 50 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/200890s001lbl.pdf	Primary	Approved 8429	ISOPTO CARPINE Approved Use Isopto Carpine is a muscarinic cholinergic agonist indicated for (1) the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; (2) the management of acute angle-closure glaucoma; (3) the prevention of postoperative elevated IOP associated with laser surgery; (4) the induction of miosis. Launch Date 2010
Acute angle-closure glaucoma 3 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/200890s001lbl.pdf	Primary	Approved 8429	ISOPTO CARPINE Approved Use Isopto Carpine is a muscarinic cholinergic agonist indicated for (1) the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; (2) the management of acute angle-closure glaucoma; (3) the prevention of postoperative elevated IOP associated with laser surgery; (4) the induction of miosis. Launch Date 2010

C_max

Value	Dose	Co-administered	Analyte	Population
15 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/020237s012lbl.pdf	5 mg 3 times / day multiple, oral dose: 5 mg route of administration: Oral experiment type: MULTIPLE co-administered:		PILOCARPINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
33 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/020237s012lbl.pdf	5 mg 3 times / day multiple, oral dose: 5 mg route of administration: Oral experiment type: MULTIPLE co-administered:		PILOCARPINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
0.76 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/020237s012lbl.pdf	5 mg 3 times / day multiple, oral dose: 5 mg route of administration: Oral experiment type: MULTIPLE co-administered:		PILOCARPINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
100% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/020237s012lbl.pdf	5 mg 3 times / day multiple, oral dose: 5 mg route of administration: Oral experiment type: MULTIPLE co-administered:		PILOCARPINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
2 % 4 times / day multiple, ophthalmic Recommended Dose: 2 %, 4 times / day Route: ophthalmic Route: multiple Dose: 2 %, 4 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200890s000MedR.pdf Page: p. 36	unhealthy, 44-75 years n = 2 Health Status: unhealthy Age Group: 44-75 years Sex: M Population Size: 2 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200890s000MedR.pdf Page: p. 36	Disc. AE: Vision blurred... AEs leading to discontinuation/dose reduction: Vision blurred (moderate, 2 patients) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200890s000MedR.pdf Page: p. 36
20 mg single, oral Overdose Dose: 20 mg Route: oral Route: single Dose: 20 mg Sources: https://pubmed.ncbi.nlm.nih.gov/15093850	unhealthy, 46 years n = 1 Health Status: unhealthy Condition: xerostomia Age Group: 46 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/15093850	Other AEs: Increased salivation, Lacrimation... Other AEs: Increased salivation (1 patient) Lacrimation (1 patient) Vomiting (1 patient) Anxiety (1 patient) Tremor (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/15093850
100 mg single, oral Overdose Dose: 100 mg Route: oral Route: single Dose: 100 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/020237s012lbl.pdf	unhealthy n = 2 Health Status: unhealthy Population Size: 2 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/020237s012lbl.pdf	Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/020237s012lbl.pdf
1.54 % 3 times / day multiple, topical Recommended Dose: 1.54 %, 3 times / day Route: topical Route: multiple Dose: 1.54 %, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/32248594/	unhealthy n = 20 Health Status: unhealthy Condition: xerostomia Population Size: 20 Sources: https://pubmed.ncbi.nlm.nih.gov/32248594/	Sources: https://pubmed.ncbi.nlm.nih.gov/32248594/

AEs

AE	Significance	Dose	Population
Vision blurred	moderate, 2 patients Disc. AE	2 % 4 times / day multiple, ophthalmic Recommended Dose: 2 %, 4 times / day Route: ophthalmic Route: multiple Dose: 2 %, 4 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200890s000MedR.pdf Page: p. 36	unhealthy, 44-75 years n = 2 Health Status: unhealthy Age Group: 44-75 years Sex: M Population Size: 2 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200890s000MedR.pdf Page: p. 36
Anxiety	1 patient	20 mg single, oral Overdose Dose: 20 mg Route: oral Route: single Dose: 20 mg Sources: https://pubmed.ncbi.nlm.nih.gov/15093850	unhealthy, 46 years n = 1 Health Status: unhealthy Condition: xerostomia Age Group: 46 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/15093850
Increased salivation	1 patient	20 mg single, oral Overdose Dose: 20 mg Route: oral Route: single Dose: 20 mg Sources: https://pubmed.ncbi.nlm.nih.gov/15093850	unhealthy, 46 years n = 1 Health Status: unhealthy Condition: xerostomia Age Group: 46 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/15093850
Lacrimation	1 patient	20 mg single, oral Overdose Dose: 20 mg Route: oral Route: single Dose: 20 mg Sources: https://pubmed.ncbi.nlm.nih.gov/15093850	unhealthy, 46 years n = 1 Health Status: unhealthy Condition: xerostomia Age Group: 46 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/15093850
Tremor	1 patient	20 mg single, oral Overdose Dose: 20 mg Route: oral Route: single Dose: 20 mg Sources: https://pubmed.ncbi.nlm.nih.gov/15093850	unhealthy, 46 years n = 1 Health Status: unhealthy Condition: xerostomia Age Group: 46 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/15093850
Vomiting	1 patient	20 mg single, oral Overdose Dose: 20 mg Route: oral Route: single Dose: 20 mg Sources: https://pubmed.ncbi.nlm.nih.gov/15093850	unhealthy, 46 years n = 1 Health Status: unhealthy Condition: xerostomia Age Group: 46 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/15093850

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1737	substrate 1037	substrate 1217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP2A6 707 CYP3A 214 CYP2D1 6	esterase 72 CYP2A6 543 CYP1A2 1054 CYP2C19 991 CYP2E1 667 BCRP 561

Drug as perpetrator

Target	Modality	Activity
CYP3A 298	inhibitor 3277 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1510190/pdf/brjpharm00164-0104.pdf#page=3 Page: 3.0	moderate
CYP2A6 739	inhibitor 3277 Sources: https://www.fda.gov/media/79033/download#page=3 Page: 3.0	yes [Ki 1 uM]
CYP2D1 8	inhibitor 3277 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3572744/	yes [Ki 360 uM]

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP1A2 1054	substrate 3367 Sources: https://www.fda.gov/media/79033/download#page=20 Page: 20.0	weak	unlikely (co-administration study) Comment: Given the low systemic exposure following topical ocular administration of ISOPTO® Carpine, clinically relevant drug-drug interactions based on CYP450 interactions is not expected for ISOPTO Carpine Sources: https://www.fda.gov/media/79033/download#page=20 Page: 20.0
CYP2C19 991	substrate 3367 Sources: https://www.fda.gov/media/79033/download#page=20 Page: 20.0	weak	unlikely (co-administration study) Comment: Given the low systemic exposure following topical ocular administration of ISOPTO® Carpine, clinically relevant drug-drug interactions based on CYP450 interactions is not expected for ISOPTO Carpine Sources: https://www.fda.gov/media/79033/download#page=20 Page: 20.0
CYP2C9 1037	substrate 3367 Sources: https://www.fda.gov/media/79033/download#page=20 Page: 20.0	weak	unlikely (co-administration study) Comment: Given the low systemic exposure following topical ocular administration of ISOPTO® Carpine, clinically relevant drug-drug interactions based on CYP450 interactions is not expected for ISOPTO Carpine Sources: https://www.fda.gov/media/79033/download#page=20 Page: 20.0
CYP2D6 1217	substrate 3367 Sources: https://www.fda.gov/media/79033/download#page=20 Page: 20.0	weak	unlikely (co-administration study) Comment: Given the low systemic exposure following topical ocular administration of ISOPTO® Carpine, clinically relevant drug-drug interactions based on CYP450 interactions is not expected for ISOPTO Carpine Sources: https://www.fda.gov/media/79033/download#page=20 Page: 20.0
CYP2E1 667	substrate 3367 Sources: https://www.fda.gov/media/79033/download#page=20 Page: 20.0	weak	unlikely (co-administration study) Comment: Given the low systemic exposure following topical ocular administration of ISOPTO® Carpine, clinically relevant drug-drug interactions based on CYP450 interactions is not expected for ISOPTO Carpine Sources: https://www.fda.gov/media/79033/download#page=20 Page: 20.0
CYP3A4 1737	substrate 3367 Sources: https://www.fda.gov/media/79033/download#page=20 Page: 20.0	weak	unlikely (co-administration study) Comment: Given the low systemic exposure following topical ocular administration of ISOPTO® Carpine, clinically relevant drug-drug interactions based on CYP450 interactions is not expected for ISOPTO Carpine Sources: https://www.fda.gov/media/79033/download#page=20 Page: 20.0
BCRP 561	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/25755207/	yes
esterase 72	substrate 3367 Sources: https://www.fda.gov/media/79033/download#page=3 Page: 3.0	yes
CYP2A6 543	substrate 3367 Sources: https://www.fda.gov/media/79033/download#page=3 Page: 3.0	yes	unlikely (co-administration study) Comment: Given the low systemic exposure following topical ocular administration of ISOPTO® Carpine, clinically relevant drug-drug interactions based on CYP450 interactions is not expected for ISOPTO Carpine Sources: https://www.fda.gov/media/79033/download#page=3 Page: 3.0

Sourcing

Vendor/Aggregator	ID	URL
AA Blocks	AA00GRLD	https://www.aablocks.com/goods/Goods/detail?id=AA00GRLD
Acorn PharmaTech	ACN-035822	http://www.acornpharmatech.com/
Alfa Chemistry	AP92137	https://reagents.alfa-chemistry.com/product/pilocarpine-cas-92-13-7-18590.html
Alichem	69004656	http://www.alichem.com/en/products/92-13-7.html
Aurora Fine Chemicals LLC	A18.030.974	http://online.aurorafinechemicals.com/info?ID=A18.030.974
ChemMol	49426222	http://www.chemmol.com/chemmol/49426222.html
ChemMol	99173770	http://www.chemmol.com/chemmol/99173770.html
Chemspace	CSSB00016990803	https://chem-space.com/CSSB00016990803
Hairui	HR101326	http://www.hairuichem.com/en/product/54-71-7.html
Hairui	HR142167	http://www.hairuichem.com/en/product/92-13-7.html
LGC Standards	DRE-A16208380AL-100	https://www.lgcstandards.com/US/en/p/DRE-A16208380AL-100
LGC Standards	DRE-C16208380	https://www.lgcstandards.com/US/en/p/DRE-C16208380
Lab Network	LN00331142	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00331142
MolPort	MolPort-002-512-506	https://www.molport.com/shop/molecule-link/MolPort-002-512-506
OChem	12013	http://www.ocheminc.com/index.php?act=psearch&pid=092P137
R&D Chemicals	1835	http://www.rdchemicals.com/chemicals.php?mode=details&mol_id=8154
Smolecule	S539680	http://www.smolecule.com/products/s539680
Smolecule	S772644	https://www.smolecule.com/products/s772644
THE BioTek	bt-278347	https://www.thebiotek.com/product/inhibitors/bt-278347
THE BioTek	bt-308560	https://www.thebiotek.com/product/others/bt-308560
abcr GmbH	AB167837	http://www.abcr.com/shop/en/AB167837
mcule	MCULE-2634151840	https://mcule.com/MCULE-2634151840/

PubMed

Title	Date	PubMed
Multiple pilocarpine-induced status epilepticus in developing rats: a long-term behavioral and electrophysiological study.	2000	10999521
Remodeling dendritic spines of dentate granule cells in temporal lobe epilepsy patients and the rat pilocarpine model.	2000	10999513
Nonconvulsive status epilepticus in rats: impaired responsiveness to exteroceptive stimuli.	2000 Dec 20	11099755
Motor and electrographic response of refractory experimental status epilepticus in rats and effect of calcium channel blockers.	2000 Feb	11218825
In vivo study of the effect of valpromide and valnoctamide in the pilocarpine rat model of focal epilepsy.	2000 Nov	11205735
Rapid alterations in diffusion-weighted images with anatomic correlates in a rodent model of status epilepticus.	2000 Nov-Dec	11110536
Flumazenil prevents diazepam-elicited anticonvulsant action and concomitant attenuation of glutamate overflow.	2000 Oct 27	11050301
Lipid peroxidation in hippocampus early and late after status epilepticus induced by pilocarpine or kainic acid in Wistar rats.	2000 Sep 22	10984636
Synchronized feeding as a "conditioned stimulus" for overt seizures in chronically (limbic) epileptic rats: a model for "psychogenic seizures" with complex partial epilepsy.	2001	11264918
A new medication for treatment of dry mouth in Sjögren's syndrome.	2001 Apr	11404944
Immediate diode laser peripheral iridoplasty as treatment of acute attack of primary angle closure glaucoma: a preliminary study.	2001 Apr	11316102
2-chloro-N(6)-cyclopentyladenosine-elicited attenuation of evoked glutamate release is not sufficient to give complete protection against pilocarpine-induced seizures in rats.	2001 Apr	11311893
Impaired neurotransmitter release from lacrimal and salivary gland nerves of a murine model of Sjögren's syndrome.	2001 Apr	11274068
Stress response to surgical procedures in the submandibular region and its influence on salivary secretion in mice.	2001 Apr	11269873
Initiation of network bursts by Ca2+-dependent intrinsic bursting in the rat pilocarpine model of temporal lobe epilepsy.	2001 Apr 1	11283235
Exploring the potential for subtype-selective muscarinic agonists in glaucoma.	2001 Apr 27	11392632
Neostriatal muscarinic receptor subtypes involved in the generation of tremulous jaw movements in rodents implications for cholinergic involvement in parkinsonism.	2001 Apr 27	11392629
Beta-adrenergic blocker therapy and the trabecular meshwork.	2001 Feb	11372544
Randomized double blind, placebo-controlled study of pilocarpine administered during head and neck irradiation to reduce xerostomia.	2001 Feb	11336078
Brief successive temporal observational sampling as a possible indicator of daily overt seizure activity in epileptic rats.	2001 Feb	11322611
The acute effect of pilocarpine on pulsatile ocular blood flow in ocular hypertension.	2001 Feb	11318298
Twenty-four hour intraocular pressure reduction with latanoprost compared with pilocarpine as third-line therapy in exfoliation glaucoma.	2001 Feb	11318297
An animal model of nonconvulsive status epilepticus: a contribution to clinical controversies.	2001 Feb	11240586
G(q/11) and G(i/o) activation profiles in CHO cells expressing human muscarinic acetylcholine receptors: dependence on agonist as well as receptor-subtype.	2001 Feb	11181437
Regional and subunit-specific downregulation of acid-sensing ion channels in the pilocarpine model of epilepsy.	2001 Feb	11162239
The role of sensory signals from the insect coxa-trochanteral joint in controlling motor activity of the femur-tibia joint.	2001 Feb	11160496
Do recurrent febrile convulsions decrease the threshold for pilocarpine-induced seizures? Effects of nitric oxide.	2001 Feb 28	11248357
Protection by selenium of lead-acetate-induced alterations on rat submandibular gland function.	2001 Jan	11339622
Uveal effusion after cataract surgery: an echographic study.	2001 Jan	11150272
Xerostomia, xerophthalmia, and plasmacytic infiltrates of the salivary glands (Sjögren's-like syndrome) in a cat.	2001 Jan 1	11149716
Innervation of sweat glands in the forehead. A study in patients with Horner's syndrome.	2001 Jan 15	11166792
[Dry mouth].	2001 Jan 31	11252939
Reliable measurement of mouse intraocular pressure by a servo-null micropipette system.	2001 Jul	11431452
Prophylactic effects of pilocarpine hydrochloride on xerostomia models induced by X-ray irradiation in rats.	2001 Jul	11422222
Poly(2-hydroxyethyl methacrylate) film as a drug delivery system for pilocarpine.	2001 Jul	11396879
Evaluation of spontaneous contamination of ocular medications.	2001 Jul-Aug	11399868
Activity-induced expression of common reference genes in individual cns neurons.	2001 Jun	11406652
Salivary scintigraphy for assessing the protective effect of pilocarpine in head and neck irradiated tumours.	2001 Jun	11403176
Behavioral and electroencephalographic analysis of seizures induced by intrahippocampal injection of granulitoxin, a neurotoxic peptide from the sea anemone Bunodosoma granulifera.	2001 Jun	11378671
Acupuncture for pilocarpine-resistant xerostomia following radiotherapy for head and neck malignancies.	2001 Jun 1	11380221
Modulators with convergent cellular actions elicit distinct circuit outputs.	2001 Jun 1	11356892
Agonistic behavior in groups of limbic epileptic male rats: pattern of brain damage and moderating effects from normal rats.	2001 Jun 29	11423076
Long-term alteration of calcium homeostatic mechanisms in the pilocarpine model of temporal lobe epilepsy.	2001 Jun 8	11382382
Cocaine abuse, generalized myasthenia, complete external ophthalmoplegia, and pseudotonic pupil.	2001 Mar	11262695
Brain-derived neurotrophic factor superinduction parallels anti-epileptic--neuroprotective treatment in the pilocarpine epilepsy model.	2001 Mar	11259499
Lithium does not synergize the peripheral action of cholinomimetics as seen in the central nervous system.	2001 Mar 23	11324716
In vivo evaluation of submicron emulsions with pilocarpine: the effect of pH and chemical form of the drug.	2001 Mar-Apr	11253934
Amino acid derivatives with anticonvulsant activity.	2001 May	11383620
Lack of effect of mossy fiber-released zinc on granule cell GABA(A) receptors in the pilocarpine model of epilepsy.	2001 May	11353010
Calculation of the uncertainty in complication probability for various dose-response models, applied to the parotid gland.	2001 May 1	11316558

Patents

Sample Use Guides

In Vivo Use Guide

Ophthalmic solution: Instill one drop in the eye(s) up to four times daily. Oral formulation: the recommended dose is 5 mg taken three times a day (Head and Neck Cancer Patients) or 5 mg taken four times a day (Sjogren's Syndrome Patients).

Route of Administration: Other

In Vitro Use Guide

Rat submandibular gland cells were treated wth 100 uM pilocarpine. The drug elicited a small and sustained increase in [Ca2+]i, indicating that pilocarpine acts as a partial agonist for mAChR-mediated Ca2+ responses.

Name

Type

Language

PILOCARPINE NITRATE

Common Name

English

PILOCARPINE NITRATE [MART.]

Common Name

English

PILOCARPINE NITRATE [USP MONOGRAPH]

Common Name

English

PILOCARPINUM NITRICUM

Common Name

English

2(3H)-FURANONE, 3-ETHYLDIHYDRO-4-((1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-, (3S-CIS)-, MONONITRATE

Systematic Name

English

PILOCARPINE SUBNITRATE

Common Name

English

PILOCARPINE NITRATE [EP MONOGRAPH]

Common Name

English

PILOCARPINE NITRATE [VANDF]

Common Name

English

PILOCARPINE NITRATE [WHO-IP]

Common Name

English

PILOCARPINE NITRATE [USP-RS]

Common Name

English

Pilocarpine mononitrate

Common Name

English

PILOCARPINI NITRAS [WHO-IP LATIN]

Common Name

English

NSC-757282

Code

English

Pilocarpine nitrate [WHO-DD]

Common Name

English

PILOCARPINE NITRATE [MI]

Common Name

English

PILOCARPINE NITRATE [EP IMPURITY]

Common Name

English

PILAGAN

Brand Name

English

PILOCARPINUM NITRICUM [HPUS]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C47796